6‐azauridine in combination chemotherapy of childhood acute myelocytic leukemia | Zendy

Walters T. R. | Zendy; Aur R. J. A. | Zendy; Hernandez K. | Zendy; Vietti T. | Zendy; Pinkel D. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

6‐azauridine in combination chemotherapy of childhood acute myelocytic leukemia

Author(s) -

Walters T. R.,

Aur R. J. A.,

Hernandez K.,

Vietti T.,

Pinkel D.

Publication year - 1972

Publication title -

cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.052

H-Index - 304

eISSN - 1097-0142

pISSN - 0008-543X

DOI - 10.1002/1097-0142(197204)29:4<1057::aid-cncr2820290455>3.0.co;2-q

Subject(s) - medicine , mercaptopurine , vincristine , myelocytic leukemia , complete remission , leukemia , acute leukemia , chemotherapy , combination chemotherapy , gastroenterology , cyclophosphamide

Seventeen children with acute myelocytic leukemia were treated with a combination of 6‐azauridine, 6‐mercaptopurine, and vincristine. Twelve attained complete bone marrow remission, and 2 achieved good partial remissions. For maintenance therapy, patients who attained remission were randomized into 2 groups: one received 6‐mercaptopurine alone; the other received a combination of 6‐mercaptopurine, 6‐azauridine, and vincristine. The median duration of hematologic remission in these groups was 7 and 6 months, respectively. Meningeal leukemia developed in 8 of 15 patients. The overall median survival time was 8 months; for those who attained remission it was 10.5 months. The combination of 6‐azauridine, 6‐mercaptopurine, and vincristine was effective for remission induction of acute myelocytic leukemia in children.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research